Medical device titan Philips is once again in the regulatory spotlight after the U.S. FDA identified non-compliance with manufacturing standards at three of its facilities, signaling a continued struggle with quality control that echoes previous consent decrees and a massive recall of sleep and respiratory devices.
The U.S. Food and Drug Administration (FDA) has recently flagged quality issues at three Philips medical device facilities, continuing a pattern of regulatory scrutiny for the Dutch medical device giant. These inspections revealed non-compliance with required manufacturing standards, leading the FDA to classify the devices made at these sites as “adulterated” under U.S. law. This latest action comes on the heels of a significant recall of sleep and respiratory devices and an earlier consent decree concerning automatic external defibrillators, highlighting a pervasive challenge in Philips’ quality control systems.
The Latest FDA Warning: October 2025 Inspections
In October 2025, the FDA issued a warning letter to Philips following inspections at facilities in Bothell, Washington; Reedsville, Pennsylvania; and Eindhoven, Netherlands. These sites are responsible for producing a range of medical equipment, including ultrasound machines, their components, and software for cardiac assessments and patient monitoring. The core issue identified was a failure to meet current good manufacturing practices (cGMP).
Despite the severity of the warning, Philips stated it takes the warning “very seriously” and has submitted a formal response to the FDA. The company continues to manufacture and sell these products and does not anticipate a material commercial impact from this particular warning letter. An analyst from ING FM, Marc Hesselink, characterized the issue as “relatively minor,” primarily related to complaint documentation, and not expected to significantly affect Philips financially, as reported by Reuters. However, this incident is not isolated.
Echoes of the Past: The 2021 Sleep Device Recall and 2024 Consent Decree
The current warning letter follows a major regulatory action taken against Philips Respironics, a subsidiary, in April 2024. A federal court ordered Philips Respironics to halt manufacturing and distribution of most sleep and respiratory devices from three Pennsylvania facilities—Murrysville, New Kensington, and Mt. Pleasant—until specific safety and compliance measures were implemented. This injunction also impacted a facility in Carlsbad, California, where manufacturing could not resume without meeting certain conditions.
This consent decree stemmed from a complaint filed by the United States alleging that Philips Respironics violated the Federal Food, Drug, and Cosmetic Act (FDCA) by manufacturing and distributing adulterated and misbranded medical devices. Specifically, the complaint highlighted failures to comply with FDCA and good manufacturing practice regulations, inadequate reporting of corrections or removals, and unapproved remediation processes for recalled ventilators. These violations were consistent with issues identified in prior FDA inspections and warning letters.
The catalyst for the 2024 action was the widespread recall in June 2021 of millions of CPAP machines, BiPAP machines, and mechanical ventilators. These devices contained polyester-based polyurethane (PE-PUR) foam for sound abatement, which was found to degrade into particles that users could ingest or inhale, and also off-gas certain chemicals. The FDA classified these as Class I recalls, the most serious type, indicating potential for serious injury or death. Efforts to remediate these devices are ongoing, with some remediated devices themselves facing additional recalls. The consent decree also included a novel provision for a remediation payment option for affected patients, as highlighted by FDA Director Jeff Shuren, M.D., J.D., of the Center for Devices and Radiological Health.
Principal Deputy Assistant Attorney General Brian Boynton emphasized the government’s commitment to enforcing federal law and preventing the marketing of adulterated devices to vulnerable patients. U.S. Attorney Eric G. Olshan for the Western District of Pennsylvania further stated that the decree established stringent thresholds for restarting production and safeguards against future violations. More details on such enforcement efforts can be found on the Justice Department’s Civil Division Consumer Protection Branch website.
A Broader Pattern: The AED Quality Control Agreement
The regulatory challenges for Philips extend even further back. An earlier consent decree involved Philips North America LLC (doing business as Philips Medical Systems and Philips Healthcare) over quality control issues with automatic external defibrillators (AEDs) and Q-CPR meters. This agreement prohibited manufacturing and distribution from facilities in Andover, Massachusetts, and Bothell, Washington, until compliance with FDCA and FDA regulations was achieved.
The complaint detailed that Philips’ AEDs and Q-CPR meters were considered adulterated due to non-compliance with cGMP and quality system (QS) regulations. Failures included inadequate processes for corrective and preventative actions, design verification and validation controls, and product specifications. Melinda Plaisier, Associate Commissioner for Regulatory Affairs at the FDA, underscored the critical nature of AEDs as life-saving tools and the risks posed by distributing adulterated products.
Under this decree, Philips’ Emergency Care and Resuscitation (ECR) business unit had to cease operations at its Massachusetts and Washington facilities until it completed corrective actions, including retaining a qualified third-party cGMP expert to inspect its operations.
Implications for Patients and the Industry
The recurring nature of FDA warnings and consent decrees against Philips across multiple product lines—from sleep and respiratory devices to defibrillators and ultrasound equipment—highlights systemic issues in the company’s manufacturing and quality assurance processes. For patients, this translates into ongoing uncertainty about the safety and reliability of critical medical devices. The widespread 2021 recall of sleep devices, in particular, left millions without essential treatment or with concerns over potential health impacts from degrading foam.
These incidents underscore the FDA‘s vital role in ensuring medical device safety and the serious consequences for manufacturers who fail to adhere to stringent quality standards. For the medical device industry as a whole, Philips‘ challenges serve as a stark reminder of the continuous need for robust quality control systems, transparency, and proactive compliance to maintain patient trust and regulatory approval. The long-term implications for Philips could include continued operational restrictions, increased compliance costs, and potential damage to its reputation in the highly competitive medical technology market.
